UniProt O43353 · PDB · AlphaFold · Substrate: MBP · Clone: aa 1-299medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 94.5% | 5.5% | 78.23 | 0.534 |
| 2 | Canertinib | 87.1% | 12.9% | 96.49 | 0.671 |
| 3 | Tivozanib | 82.7% | 17.3% | 92.42 | 0.673 |
| 4 | Alectinib | 72.8% | 27.2% | 95.49 | 0.651 |
| 5 | Erdafitinib | 72.5% | 27.5% | 95.71 | 0.737 |
| 6 | Gilteritinib | 71.1% | 28.9% | 88.97 | 0.506 |
| 7 | Lazertinib | 70.4% | 29.6% | 97.47 | 0.674 |
| 8 | Pacritinib | 70.2% | 29.8% | 88.64 | 0.452 |
| 9 | Vandetanib | 65.4% | 34.6% | 95.74 | 0.723 |
| 10 | Dabrafenib | 63.3% | 36.7% | 94.74 | 0.633 |
| 11 | Gefitinib | 57.5% | 42.5% | 99.25 | 0.650 |
| 12 | Dasatinib | 54.3% | 45.7% | 87.97 | 0.699 |
| 13 | Dacomitinib | 52.6% | 47.4% | 97.99 | 0.664 |
| 14 | Lenvatinib | 50.4% | 49.6% | 97.74 | 0.726 |
| 15 | Ibrutinib | 47.0% | 53.0% | 94.74 | 0.723 |
| 16 | Afatinib | 46.6% | 53.4% | 98.50 | 0.709 |
| 17 | Vemurafenib | 46.6% | 53.4% | 96.49 | 0.598 |
| 18 | Erlotinib | 44.7% | 55.3% | 99.75 | 0.695 |
| 19 | Encorafenib | 44.0% | 56.0% | 98.50 | 0.755 |
| 20 | Pazopanib | 41.6% | 58.4% | 97.49 | 0.672 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.16
- Epithelial log2(TPM+1): 3.69
- Fold change: 0.47
- Status: No significant change
High-confidence drugs
- Canertinib — inh 87.1% · KISS 32.35
- Ponatinib — inh 94.5% · KISS 26.49
- Tivozanib — inh 82.7% · KISS 24.22
Selectivity landscape vs inhibition on RIPK2
Each point is one of the 92 approved drugs; color = inhibition % on RIPK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…